From Boardroom to Benchtop: Paul LaViolette Joins SVLS
This article was originally published in Start Up
Executive Summary
Paul LaViolette spent more than a decade at Boston Scientific where, among other things, he helped build the company into a cardiovascular powerhouse. LaViolette announced his retirement from BSC last year and after considering a number of opportunities, decided to join Boston-based SVLS as a venture partner. LaViolette enters venture investing at a challenging time, during which the industry will face what he calls "a Darwinian process with more operational pressure" at start-ups and a likely weeding out of many companies. In this interview, LaViolette describes how the venture world of 2008 feels a lot like Boston Scientific in 1993 -- a world of small, driven companies with huge operational challenges and huge opportunities.
You may also be interested in...
Medical Device Investing: Financing in an Economic Crisis
At FDC-Windhover's October IN3 East conference, we asked a distinguished panel of experienced venture capitalists to share their insights on the downturn in medtech venture investing. We invited our panelists to weigh in on the role of the current crisis in the second and third quarter slowdown in device investing and what it would mean going forward for a sector that had been so frothy just a short time earlier.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.